Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Public ClinicalTrials.gov record NCT04901702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma
Study identification
- NCT ID
- NCT04901702
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Enrollment
- 90 participants
Conditions and interventions
Conditions
- Recurrent Ewing Sarcoma
- Recurrent Hepatoblastoma
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Solid Neoplasm
- Recurrent Neuroblastoma
- Recurrent Osteosarcoma
- Recurrent Peripheral Primitive Neuroectodermal Tumor
- Recurrent Rhabdoid Tumor
- Recurrent Rhabdomyosarcoma
- Recurrent Soft Tissue Sarcoma
- Recurrent Solid Tumor
- Recurrent Wilms Tumor
- Refractory Ewing Sarcoma
- Refractory Hepatoblastoma
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Solid Neoplasm
- Refractory Neuroblastoma
- Refractory Osteosarcoma
- Refractory Peripheral Primitive Neuroectodermal Tumor
- Refractory Rhabdoid Tumor
- Refractory Rhabdomyosarcoma
- Refractory Soft Tissue Sarcoma
Interventions
- Onivyde Drug
- Talazoparib Drug
- Temozolomide Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Months to 30 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2021
- Primary completion
- Dec 30, 2025
- Completion
- Dec 30, 2026
- Last update posted
- Apr 12, 2026
2021 – 2026
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lucille Packard Children's Hospital Stanford | Palo Alto | California | 94304 | Recruiting |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | Recruiting |
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010 | Recruiting |
| Children's Healthcare of Atlanta/Emory University School of Medicine | Atlanta | Georgia | 30322 | Not yet recruiting |
| Children's Hospital and Clinics of Minn | Minneapolis | Minnesota | 55404 | Recruiting |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | Recruiting |
| Texas Children's Hospital/ Baylor College of Medicine | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04901702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04901702 live on ClinicalTrials.gov.